top of page

ORTHOBIOLOGICS DIGEST™NUMBER 10 | NOVEMBER 9 2026: BPC-157 and the Shades of Gray

Deborah Westergaard, M.D.
Nov 9
9 min read

ORTHOBIOLOGICS DIGEST™

NUMBER 10  |  NOVEMBER 9 2026


Emerging science. Clinical perspective. Joint preservation.

Deborah Westergaard, M.D.  |  Board-Certified Anesthesiology & Pain Medicine

An editorial digest of recent reporting and peer-reviewed research. Each feature identifies its source, explains the evidence, and separates published findings from the physician’s perspective.


Inside this issue of Orthobiologic Digest

01  BPC-157, Klotho, and the Shades of Gray

02  Are We Killing the Very Cells That Help Us Heal?

03  Cleveland Clinic Puts BMAC to the Test in Hip Arthritis

04  Bone Marrow Clot vs. Concentrate: Does Simpler Mean Better?

05  Closing Perspective: Treat the Whole Joint, Not Just the Syringe

Editorial note: The first feature examines multiple linked sources; the final feature is an original closing commentary, not a fifth independent clinical study. The nine-year single-case knee report and the Alzheimer’s ultrasound trial were deliberately excluded following editorial review.


01 | BPC-157, Klotho, and the Shades of Gray: When Biohacking Challenges Conventional Medicine

The article and what it reports

Original reporting: Tom Bartlett, “Is There Anything BPC-157 Can’t Cure?”, The Atlantic, October 27, 2026. Related research: Castner et al., Nature Aging (2023); Czaplicki et al., JAMA Neurology (2026).

The Atlantic examines the growing market for BPC-157, extraordinary wellness claims, uncertain dosing and sourcing, and the limited controlled human evidence supporting musculoskeletal and other uses. It asks whether enthusiasm has outrun science. Klotho offers a revealing contrast: a 2023 primate study found that a low dose improved memory performance in a small group of older macaques, whereas higher doses did not show the same benefit. A 2026 cross-sectional study of 308 cognitively unimpaired adults found that higher naturally occurring serum Klotho was associated with better cognition despite greater brain atrophy in some analyses, particularly in the older subgroup. Neither Klotho study establishes benefit from human injections. Klotho is a protein, not a short synthetic peptide; grouping it with peptides is a discussion of experimental signaling therapies, not a claim of identical molecular classification.


Read the source

Nature Aging — Klotho in primates  https://www.nature.com/articles/s43587-023-00441-x

JAMA Neurology — serum Klotho  https://pubmed.ncbi.nlm.nih.gov/41627838/


My take — Deborah Westergaard, M.D.

I welcome critical journalism, particularly when people are being sold products with claims that have not been established in human trials. But I also believe The Atlantic’s portrayal of the biohacking community leans too heavily toward its most extravagant claims. Biohackers are not one homogeneous group. Some market unsupported promises; others ask questions that conventional research has not prioritized. We should be able to challenge the former without dismissing the latter. Innovation has shades of gray.

BPC-157 has accumulated preclinical research over decades, yet robust human efficacy and long-term safety data remain limited. I want to know why. Pharmaceutical economics is one plausible factor: when composition patents have expired or exclusivity is uncertain, financing expensive trials can be harder. That is a question about incentives, not proof that companies are suppressing an effective drug. Manufacturing, toxicology, dosing, and pharmacokinetic uncertainties also matter. The same economic tension appears in autologous blood and bone marrow therapies, where a patient’s native biological material is not simply a patentable new drug.

I have personally used physician-prescribed BPC-157 and TB-500 in an oral/sublingual formulation. That is a description of my own choice, not evidence of efficacy. I do not currently prescribe experimental peptides to my orthobiologics patients. My practice focuses on PRP, bone marrow concentrate, and precise image-guided treatment of musculoskeletal pathology. I am interested in whether peptides could one day enhance orthobiologic outcomes, but I want controlled human studies, product characterization, dosing data, and safety information before making them part of my protocols. The route of administration matters too: a marketed sublingual preparation is not evidence of demonstrated human bioavailability.

The Klotho findings fascinate me because they raise a profound question: can biological signaling preserve function even when structural aging is present? But an observational association is not a treatment result. And the conference anecdote about women in their seventies reportedly bleeding after Klotho plus another experimental compound, FLGR242, illustrates why clinical reasoning is essential. That report is unverified; we cannot call the bleeding restored menstruation or attribute it to either compound. My first question is whether someone measured the endometrial stripe and evaluated for endometrial pathology. Postmenopausal bleeding is a warning sign, not proof of rejuvenation.

Patients deserve meaningful choices, physician oversight, transparent uncertainty, and reliable quality controls. They should ask their physicians for the reasoning behind a recommendation and can use AI to explore competing interpretations—while checking AI-generated claims against original studies. Being interested in a therapy does not obligate me to prescribe it; declining to prescribe it does not mean I have dismissed its potential. Progress happens in the shades of gray, where curiosity meets evidence, skepticism meets open-mindedness, and innovation meets responsibility.


02 | Are We Killing the Very Cells That Help Us Heal?

The article and what it reports

Endo et al., Biochemical and Biophysical Research Communications, September 3, 2026 (online June 19); Liu et al., Bone Research, June 11, 2026.

The first study investigated piperlongumine, a candidate senolytic, in human osteoarthritic meniscal and cartilage cells and in a rat osteoarthritis model. It reported fewer senescence-associated cells, increased matrix-related output in laboratory cells, and reduced cartilage/meniscal degeneration and synovitis in rats. The second used a mouse Achilles tendon injury model. It found that p16-positive cells accumulated during healing and that removing them impaired collagen organization and biomechanical recovery. The authors identified a JMJD3-linked matrix-remodeling program. These are not contradictory human treatment trials: they involve different tissues, injury states, cell populations, and experimental interventions.


Read the source

September cartilage/meniscus study  https://pubmed.ncbi.nlm.nih.gov/42322814/


My take — Deborah Westergaard, M.D.

We have to start somewhere. Scientific progress requires breaking an enormously complicated process into smaller pieces and examining them carefully. But we must never forget that the pieces operate in the context of an entire human body.

A rat knee is not a human knee. Human joints differ in anatomy, loading history, biomechanics, comorbid pathology, and the decades over which degeneration develops. Likewise, a newly injured mouse Achilles tendon is not necessarily comparable to a chronically degenerative human tendon. A marker such as p16 identifies a cellular state or response; it does not tell us, by itself, whether every labeled cell is harmful or beneficial.

The practical orthobiologic question is not simply whether senescent cells are “bad.” It is which cell populations are present, when they are present, what they are doing, and whether modifying them improves meaningful human function. Could that tissue environment influence responses to PRP or BMC? Possibly—but this remains a research hypothesis. We should study the pieces and then put them back into their physiological context before changing patient care.


03 | Cleveland Clinic Puts BMAC to the Test: Why Is Hip Arthritis Still Compared With Steroids?


The article and what it reports

Cleveland Clinic Consult QD, November 2, 2026; registered study NCT04990128.

Cleveland Clinic Florida describes a single-site, randomized, participant-blinded Phase III study planning to enroll 100 patients with symptomatic hip osteoarthritis. It compares an ultrasound-guided intra-articular injection of bone marrow aspirate concentrate (BMAC) with an intra-articular triamcinolone injection. The control group undergoes a sham marrow aspiration to support blinding. Outcomes include WOMAC pain/function measures and six-minute walk performance through 12 months. Researchers also plan to characterize the BMAC cell population and examine associations with outcomes. This is an ongoing trial, not evidence that BMAC has already outperformed corticosteroids. Crucially, neither treatment arm includes targeted intraosseous augmentation.


Read the source


My take — Deborah Westergaard, M.D.

I welcome rigorous hip studies from major medical centers, particularly those that characterize the material being injected and follow outcomes over time. But I am disappointed that this study does not include an intraosseous treatment arm. That does not make the investigators wrong. Techniques evolve rapidly, and the study was designed around the approaches, training, and evidence available when its protocol was established. The work of Philippe Hernigou and others examining subchondral bone has been influential in my own approach to joint preservation.

I also question why intra-articular corticosteroids remain such a common benchmark when the long-term objective is preserving the joint. Triamcinolone is a familiar comparator, and a single injection is not equivalent to repeated injections. Nevertheless, repeated corticosteroid exposure has raised legitimate concerns about cartilage loss. Pain reduction is useful; it is not the same as structural repair. I would like more studies comparing carefully characterized BMC, standardized PRP, hyaluronic acid, and appropriate controls, with meaningful longer-term follow-up. Those alternatives have their own limitations and are not all proven to preserve cartilage.

The trial should also account for age, severity, biological dose, and other abnormalities in the hip. An intra-articular injection creates a clean research question, but the patient does not arrive with an isolated joint cavity. The labrum, cartilage, subchondral bone, capsule, tendons, and mechanics all contribute to symptoms and function. Standardizing the injectate is important. Determining whether we are treating the right anatomical target is equally important.

I speak about joint preservation from experience. I tore my labrum in 2008 and wish effective orthobiologic options had been available to me then. The physicians who treated my hip in 2023 offered comprehensive care based on the knowledge and indications available at that time; I do not fault them. My acetabular bone was treated, but progressive labral pathology eventually made replacement necessary. My surgeon performed an excellent operation, and I am grateful that I can walk without a limp. Still, I have reduced the intensity of activities I once enjoyed to protect the prosthesis. A successful hip replacement can restore enormous function without reproducing the experience of a native hip. That is why I want us to study joint preservation earlier and more comprehensively—not because surgery is never appropriate, but because preserving a functional natural joint, when possible, matters.


04 | Bone Marrow Clot vs. Concentrate: Does Simpler Mean Better?


The article and what it reports

Lana et al., Stem Cell Research & Therapy, April 29, 2026.

In a randomized, double-blind study of people aged 50–80 with Kellgren–Lawrence grade 3–4 knee osteoarthritis, investigators compared three monthly intra-articular treatments with bone marrow aspirate clot (BMA-clot) or bone marrow aspirate concentrate (BMAC). BMAC is an anticoagulated marrow aspirate processed to concentrate selected cellular components into an injectable liquid. BMA-clot instead uses the fibrin network that forms as marrow coagulates, potentially retaining cells and signaling molecules within a scaffold. Both groups improved on pain, WOMAC function, and quality-of-life measures over 12 months; between-group differences were not statistically significant. The reported pain reductions were 77% for clot and 68.4% for BMAC, a numerical difference that did not establish superiority. There was no saline or usual-care control, so improvements cannot all be attributed confidently to the biological product.


Read the source


My take — Deborah Westergaard, M.D.

The appeal of a marrow clot is understandable: fewer processing steps may save time and cost. But the practical question is whether it is as predictable to deliver. A fibrin-rich preparation may behave differently from anticoagulated BMC, especially as clot formation progresses. Even with properly anticoagulated concentrate, I sometimes encounter resistance through a 25-gauge needle. I also perform intraosseous injections, where trabecular back-pressure can make delivery difficult even with substantially larger access devices. This trial studied intra-articular injections, so it does not establish how a marrow clot would behave in bone.

I have not used a marrow-clot preparation myself, and I would like detailed handling reports from clinicians who have. We should distinguish material that clots after delivery from a fully formed clot being pushed through a needle. The paper raises an interesting biological question—whether concentration is the only variable that matters—but it does not prove that concentration is unnecessary.

Given the lack of a demonstrated clinical advantage for clot in this trial, beyond possible processing simplicity and cost, I am not changing my current BMC protocol. When my objective is to help a patient avoid joint replacement, I will continue evaluating and treating the joint, the subchondral bone when indicated, and relevant disrupted soft tissues. A simpler preparation is worth studying. It is not automatically a better treatment.


05 | Closing Perspective: Treat the Whole Joint, Not Just the Syringe


Original editorial conclusion

The most important lesson of this issue is not that one peptide, cell population, or marrow preparation has solved degeneration. It is that biology is context-dependent. What matters in a laboratory cell, an injured mouse tendon, or an isolated joint compartment may not predict what matters in a person whose joint has been changing for decades.

We need controlled trials, consistent characterization of biological preparations, adequate follow-up, and patient-centered functional outcomes. We also need better descriptions of the anatomy we are treating: cartilage, labrum, tendon, ligament, capsule, and subchondral bone. The future of orthobiologics is not simply a better injectate. It is understanding the whole joint—and intervening early enough that replacement may never become necessary.


Evidence and editorial disclosures

The physician perspectives above are editorial commentary, not results of the cited studies. The emerging treatments discussed are not established substitutes for indicated surgery or standard care. Animal and observational findings cannot establish human efficacy; lack of statistical superiority does not prove equivalence. Product preparation, legal status, and evidence standards vary by intervention and jurisdiction. The author describes personal peptide use solely to disclose her perspective, not to recommend patient use.


ORTHOBIOLOGICS DIGEST™ • NO. 10 • NOVEMBER 2026


Comments


COSTS & COVERAGE

What will treatment cost?

A joint is a working system of cartilage, bone, ligaments, tendons, and supporting muscles. Your plan may include an injection into the joint space and targeted treatment of other tissues contributing to pain or dysfunction. Dr. Westergaard selects the orthobiologic, concentration, and dose for each appropriate target, considering the tissue involved, severity of the condition, your age, and clinical findings. Your estimate reflects the scope of your recommended care. Your evaluation is billed separately, and you receive an individualized written procedure estimate before scheduling.

​

​Orthobiologic procedures are generally not covered by traditional insurance. Regenexx employer benefits may cover eligible treatment, depending on your plan. CareCredit is available, subject to credit approval.

bottom of page